Management of Patients with Colorectal Cancer: Elsevier Office of Continuing Medical Education Independent Conference Highlights of the ASCO-GI 2018 Symposium*
*This webcast is not endorsed by the conference organizer. The Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference-coverage educational programs.
This conference reporter webcast on colorectal cancer is based on a roundtable discussion by three experts. During the webcast they provide an overview of challenges in the management of colorectal cancer and summarize and discuss recent data presented during the ASCO-GI 2018 Symposium. The experts examine clinical trial outcomes of targeted therapies for colorectal cancer and address the question of how current, novel, and emerging treatment options (when approved) could be implemented in individualized treatment plans to optimize treatment selection and outcomes for patients with colorectal cancer.
This activity has been designed to meet the educational needs of a broad audience, including oncologists, gastroenterologists, surgical oncologist, radiation oncologists, and other healthcare professionals responsible for the diagnosis, treatment, or management of patients with colorectal cancer.
After viewing this activity, participants will be better able to:
- Explain the molecular targets of colorectal cancer therapy and apply the optimal molecular screening method to guide the selection of targeted therapies
- Analyze the clinical trial data of current, novel, and emerging targeted therapies presented at the ASCO-GI 2018 Symposium
- Apply the above knowledge to develop data-driven, individualized treatment plans to improve treatment selection and outcomes for patients with colorectal cancer
|John L. Marshall, MD|
Georgetown University Medical Center
Washington, DC, USA
|Johanna C. Bendell, MD|
Nashville, TN, USA
Tanios S. Bekaii-Saab, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this Continuing Medical Education (CME) activity:
|Name of Faculty or Presenter||Relationship Identified With:|
|John L. Marshall, MD|
Consultant/Advisor: Amgen Inc.; Bayer AG; Bristol-Myers Squibb Company; Celgene Corporation; Genentech, Inc.; Merck & Co., Inc; and Taiho Pharmaceutical Co., LTD.
Speakers Bureau: Amgen Inc.; Bayer AG; Bristol-Myers Squibb Company; Celgene Corporation; Genentech, Inc.; Merck & Co., Inc; and Taiho Pharmaceutical Co., LTD.
|Johanna C. Bendell, MD|
Nothing to disclose
|Tanios S. Bekaii-Saab, MD||Consultant/Advisor: AbbVie Inc.; ARMO BioSciences; Exelixis; Inc.; Merck & Co., Inc; SillaJen Inc.|
Non-faculty: Sandy Breslow; Alison Kemp; Bernard M. Abrams, MD; Joke Artmanni; Elena Knoche, PhD; Marijke Verhaaf; hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Amgen.
Jointly provided by the Elsevier Office of Continuing Medical Education and Ology Medical Education.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Ology Medical Education. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Ology Medical Education, and Amgen do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician